Table 4.
Summary of management of cardiac Myxoma participants according to medication and surgical intervention. ACEi/ARB refers to angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, and MRA refers to mineralocorticoid receptor antagonists.
| Management | No. Of participants (%) | p-value | ||
|---|---|---|---|---|
| Overall (n = 64) | Survived (n = 53) | Deceased (n = 11) | ||
| Medication Prescribed | 50 (78.1) | 40 (75.5) | 10 (90.9) | 0.47 |
| Antiplatelet | 28 (43.8) | 20 (37.7) | 8 (72.7) | 0.07 |
| Anticoagulant | 16 (25.0) | 14 (26.4) | 2 (18.2) | 0.85 |
| Warfarin | 11 (17.2) | 10 (18.9) | 1 (9.1) | 0.73 |
| Direct Oral Anticoagulant | 5 (7.8) | 4 (7.5) | 1 (9.1) | 1.0 |
| Beta Blockers | 26 (40.6) | 20 (37.7) | 6 (54.5) | 0.49 |
| Calcium Channel Blocker | 9 (14.1) | 8 (15.1) | 1 (9.1) | 0.96 |
| Statins | 36 (56.2) | 30 (56.6) | 6 (54.5) | 1.0 |
| ACEi/ARB | 13 (20.3) | 6 (11.1) | 7 (63.6) | < 0.001 |
| MRA | 3 (4.7) | 3 (5.7) | 0 (0.0) | 0.98 |
| Diuretics | 11 (17.2) | 7 (13.2) | 4 (36.4) | 0.16 |
| Surgical Intervention | 48 (75.0) | 44 (83.0) | 4 (36.4) | 0.004 |